Medline, a leading medical product distributor and manufacturer, and materials science innovator Hologenix® are excited to announce that they have partnered on a new line of CURAD® brand orthopedic products powered by CELLIANT® infrared technology.
CELLIANT, the flagship product of Hologenix, is a proprietary blend of natural minerals that allows textiles to convert body heat into infrared energy, returning it to the body and temporarily increasing local blood flow and cellular oxygenation. This aids significantly in muscle recovery, increases endurance and improves overall performance in healthy individuals, among other benefits.
“This is another innovative introduction for the time-honored CURAD brand,” said Sarah Cooper, Senior Manager, Product Management at Medline Industries, LP. “Our partnership with Hologenix substantially increases our commitment to expand the use of infrared in our orthopedic soft goods market, where we think it has great potential.”
“We are honored indeed to partner with such a renowned company as Medline,” said Seth Casden, Hologenix Co-Founder and CEO. “For us, this represents a major expansion of CELLIANT infrared (IR) bio-responsive textiles into the sports medicine field.”
Several years in development, the new CURAD orthopedic product line powered by CELLIANT will officially launch later this year.
*The FDA determined products containing CELLIANT® are medical devices because they are intended to temporarily increase blood flow and local circulation at the site of application in healthy individuals.
As part of the 513(g) submission process, the FDA reviewed and commented on appropriate health and wellness claims for CELLIANT® products. The FDA has determined that CELLIANT® products are medical devices as defined in section 201(h) of the Federal Food, Drug and Cosmetic Act and are general wellness products.
The FDA has not approved or designated CELLIANT® products for any purpose and has not made any determination about, or endorsement of, its stated use or benefits.
CELLIANT® is designated as a Class 1 Medical Device in Australia, Canada, the European Union, Japan, New Zealand, the United Arab Emirates and the United Kingdom. CELLIANT® is cleared to market in China, India, Indonesia, Korea, Mexico, Peru, Philippines, Singapore, Taiwan, Thailand and Vietnam, with more countries and regions to follow.
